A Phase 2 Open-label Study to Assess the Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Patients with Metastatic Advanced Stage Ovarian Cancer

In this study, the safety, tolerability, and anti-tumor activity of HCW9218 in combination with chemotherapy will be assessed in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy.

开始日期2024-05-10

申办/合作机构

University of Pittsburgh

[+1]

NCT05304936

/ Completed临床1/2期

A Phase 1b/2 Study of HCW9218, a Bifunctional TGF-β (Transforming Growth Factor Beta) Antagonist/IL-15 (Interleukins) Protein Complex, for Advanced Pancreatic Cancer

This is a Phase 1b/2, open-label, multi-center, competitive enrollment and dose-escalation study of HCW9218 in patients with advanced/metastatic pancreatic cancer.

开始日期2022-10-17

申办/合作机构

ImmunityBio, Inc.

NCT05322408

/ Completed临床1期IIT

A Phase I Study of HCW9218, a Bifunctional TGF-B; Antagonist/IL-15 Protein Complex, in Select Advanced Solid Tumors After Failing at Least Two Prior Therapies

This is a single center, Phase I dose finding study of HCW9218 for the treatment of advanced/metastatic solid tumor cancer (except pancreatic and primary brain cancers). HCW9218 is a novel bi-functional fusion protein complex administered by subcutaneous (SC) injection. It is comprised of a soluble fusion of two human TGFβRII domains, human tissue factor, and human IL-15, and a second soluble fusion of two human TGFβRII domains and a sushi domain of human IL-15Rα. HCW9218 activates IL-15R signaling on effector immune cells and the dimeric TGFβRII functions as a "trap" for all three human TGF-β isoforms.

开始日期2022-04-01

申办/合作机构

University of Minnesota Masonic Cancer Center

100 项与 HCW-9218 相关的临床结果

登录后查看更多信息

100 项与 HCW-9218 相关的转化医学

登录后查看更多信息

100 项与 HCW-9218 相关的专利（医药）

登录后查看更多信息

项与 HCW-9218 相关的文献（医药）

2025-12-01·Journal for ImmunoTherapy of Cancer

TGF-βRII/IL-15 immunotherapeutic complex targets exhausted CD8 ⁺ T-cell subsets in lymph nodes and tumors

Article

作者: Gilkes, Crystal ; Miller, Jeffrey S ; Krull, Jordan ; Chaturvedi, Pallavi ; Farzaneh, Hamidreza ; Teodorescu, Rachael ; Kanakaraj, Leah ; Zhu, Xiaoyun ; Valderrama, Natalia ; Patel, Manish R ; Larson, Megan ; Kong, Lin ; Gonzalez, Neicy ; Xing, Jilan ; Liu, Bai ; Chung, Dongjun ; Gomez, Lucas ; Thompson, Alyssa ; Wong, Hing C ; You, Lijing ; Wang, Zheng ; Rubinstein, Mark P ; Egan, Jack O ; George, Varghese K ; Echeverri, Christian ; Shrestha, Niraj ; Geller, Melissa A ; Liu, Xianglan ; Wangen, Rose ; Rodriguez, Reynier ; Rhode, Peter R ; Felices, Martin ; Xie, Juan ; Leclerc, Gilles Michel ; Gutierrez, Ana K Karen ; Bialik, Ann ; Cao, Qing

Background:

Stem-like progenitor exhausted CD8 + T cells (T PEX ), located within the tumor-draining lymph nodes (TDLNs), are responsible for maintaining tumor-specific responses in cancer. Although cytokines such as interleukin (IL)-15 are known to expand CD8 + T-cell subsets, transforming growth factor (TGF)-β in the TDLN is known to arrest the egress of these T PEX to the tumor microenvironment. We hypothesized that combining IL-15 stimulatory and TGF-β blocking activity would boost antitumor responses mediated by T PEX in the TDLN.

Methods:

We developed a bifunctional TGF-βRII/IL-15 protein complex (HCW9218) and evaluated its antitumor activity in two murine models of melanoma and breast cancer. Peripheral blood, TDLN and tumor-infiltrating CD8 + T cells were characterized by flow cytometry following a single subcutaneous dose (s.c.) of HCW9218. Transcription profiling of CD8 + T cells in both murine models was performed. Synergistic activity of HCW9218 with immune-checkpoint inhibitors (ICIs) was evaluated. Finally, safety and immune profiling in patients with chemo-refractory/relapsed solid tumors was performed in a Phase 1 dose-escalating trial.

Results:

HCW9218 was capable of localizing to the TDLNs and tumors after s.c. administration, neutralized TGF-β, expanded T PEX in TDLNs, increased chemokine-expressing effectors in peripheral circulation and promoted their infiltration into murine tumors. These data were corroborated in RNA sequencing analysis of TDLNs. ICIs significantly enhanced the effects of HCW9218 on T PEX and synergistically improved HCW9218 antitumor efficacy in melanoma and reduced spontaneous lung metastasis in breast cancer models. In a Phase 1 clinical trial, HCW9218 monotherapy was well-tolerated, reduced serum TGF-β levels, promoted and sustained CD8 + T-cell expansion in peripheral blood and CD8 + T-cell infiltration in tumor biopsies. Stable disease was reported for four of six subjects (67%) with advanced ovarian cancer treated with HCW9218.

Conclusions:

Our findings demonstrate that combination therapy targeting immune cells critical for antitumor responses and blocking immune-suppressive environment significantly improves antitumor therapeutic efficacy. These findings provide a strong basis for using HCW9218 to enhance the efficacy of ICIs against solid tumors in the clinical setting.

2025-09-03·Journal of immunoassay & immunochemistry

Development of analytical methods for detection of anti-drug antibodies neutralizing IL-15 and TGF-β RII activity

Article

作者: Leclerc, Gilles M. ; Egan, Jack O. ; Wong, Hing C. ; Rhode, Peter R. ; You, Lijing ; Shrestha, Niraj

To comply with regulatory guidelines and ensure that biopharmaceutical agents meet safety and efficacy, we developed an analytical method to detect anti-drug antibodies (ADAs) generated in response to HCW9218, a fusion molecule containing the human soluble TGF-β RII and IL-15/IL-15 Rα sushi domains. The method demonstrated a sensitivity of 34.6 ng/mL with a suitably high degree of specificity, selectivity, and precision. To assess the neutralizing capacity of ADAs, we developed cell-based assays specific to IL-15 and TGF-β RII. These assays effectively discriminated the neutralizing activity of sera spiked with neutralizing antibody (NAb). The determination of positive NAb was based on absorbances corresponding to a threshold value of 30% inhibition of IL-15 or TGF-β RII activity. Each assay was validated using human sera from ongoing clinical trials. ADAs were detected in most sera tested with titers less than 10,000. None of the sera inhibited IL-15 and TGF-β RII activity by more than 30%. Interestingly, circulating TGF-β present in sera mimicked the action of NAb by binding to soluble TGF-β RII resulting in higher baseline neutralization activity. These methods proved to be suitable for detection of ADAs and NAbs in HCW9218 clinical samples or analogs sharing similar receptor/cytokine subunits and/or downstream signaling pathways.

2022-03-01·Molecular therapy : the journal of the American Society of Gene Therapy1区 · 医学

Immunotherapeutic HCW9218 augments anti-tumor activity of chemotherapy via NK cell-mediated reduction of therapy-induced senescent cells

1区 · 医学

Article

作者: Wong, Hing C ; Zhu, Xiaoyun ; You, Lijing ; Jeng, Emily K ; Liu, Bai ; Kong, Lin ; Spanoudis, Catherine ; Echeverri, Christian ; Chaturvedi, Pallavi ; Wang, Meng ; George, Varghese ; Shrestha, Niraj ; Rhode, Peter R ; D'Eramo, Francesca ; Dee, Michael J ; Egan, Jack ; Fang, Byron ; Gallo, Victor

Therapy induced senescence (TIS) in tumors and TIS cancer cells secrete proinflammatory senescence-associated secretory phenotype (SASP) factors. SASP factors promote TIS cancer cells to re-enter the growth cycle with stemness characteristics, resulting in chemo-resistance and disease relapse. Herein, we show that the immunotherapeutic HCW9218, comprising transforming growth factor-β (TGF-β) receptor II and interleukin (IL)-15/IL-15 receptor α domains, enhances metabolic and cytotoxic activities of immune cells and reduces TIS tumor cells in vivo to improve the efficacy of docetaxel and gemcitabine plus nab-paclitaxel against B16F10 melanoma and SW1990 pancreatic tumors, respectively. Mechanistically, HCW9218 treatment reduces the immunosuppressive tumor microenvironment and enhances immune cell infiltration and cytotoxicity in the tumors to eliminate TIS cancer cells. Immuno-depletion analysis suggests that HCW9218-activated natural killer cells play a pivotal role in TIS cancer cell removal. HCW9218 treatment following docetaxel chemotherapy further enhances efficacy of tumor antigen-specific and anti-programmed death-ligand 1 (PD-L1) antibodies in B16F10 tumor-bearing mice. We also show that HCW9218 treatment decreases TIS cells and lowers SASP factors in off-target tissues caused by chemotherapy of tumor-bearing mice. Collectively, HCW9218 has the potential to significantly enhance anti-tumor efficacy of chemotherapy, therapeutic antibodies, and checkpoint blockade by eliminating TIS cancer cells while reducing TIS-mediated proinflammatory side effects in normal tissues.

项与 HCW-9218 相关的新闻（医药）

2026-03-18

·allsci.com

HCW Biologics hands Phase I development of tri-specific fusion immunotherapeutic to China’s Trimmune

HCW Biologics Inc. (NASDAQ: HCWB), a Florida-based biopharma, has closed an exclusive worldwide license for HCW11-006, a preclinical fusion immunotherapeutic, signed with Beijing Trimmune Biotech Co., Ltd. Trimmune is a newly formed entity established by WY Biotech Co., Ltd., a China-based recombinant protein and gene/cell therapy developer, and HCW Biologics. The license deal grants Trimmune rights to develop and commercialize HCW11-006 globally, with a Phase I clinical study in China expected in the first half of 2027. Trimmune will bear all costs associated with that trial, as per the deal announcement. The deal terms include an upfront payment of USD 7.0 million, comprised of USD 3.5 million in cash and USD 3.5 million of equity in Trimmune. HCW Biologics is also eligible for development milestone payments along with double-digit royalties on future product sales. The company is further entitled to a portion of proceeds from any future transactions involving the licensed molecule. Financial terms beyond these categories were not disclosed. Trimmune’s investors include CITIC Medical Fund and TigerYeah Capital Fund of TigerMed. A structural element of this immunotherapy licensing deal is a payment-free, milestone-free, and royalty-free option retained by HCW Biologics to recapture all rights for in vivo applications of HCW11-006 in the United States, Canada, Central America, and South America. That option becomes exercisable after the conclusion of the Phase I clinical trial in China. This provision means HCW Biologics could regain the Americas territory without additional cost, using Trimmune-funded Phase I data to inform its decision. The deal also provides Trimmune with an option to license exclusive regional China rights to HCW9302, a separate clinical-stage molecule from HCW Biologics currently in a Phase I study in alopecia areata (NCT07049328). Deal context HCW11-006 is a multi-functional fusion protein biologic generated from HCW Biologics’ proprietary TRBC drug discovery and development platform. The company has stated it has constructed over 50 molecules using the TRBC platform, including HCW11-002, HCW11-018, and HCW11-040, though clinical details on those assets have not been disclosed. HCW Biologics HCW11-006 is designed to integrate functional domains of interleukin-12, interleukin-15, and a PD-L1 blocking component into a single engineered construct. The molecule is intended to simultaneously activate natural killer cells and T cells through cytokine receptor signaling while blocking the PD-1/PD-L1 immune checkpoint axis. No clinical trials for HCW11-006 are currently registered on clinicaltrials.gov. The asset remains in preclinical development. The HCW Biologics exclusive license agreement fits within the company’s stated strategy of using business development to finance clinical programs. HCW Biologics operates a second platform, TOBI, which generated HCW9302 and HCW9218, a fusion protein that has been in a Phase 1b study in advanced pancreatic cancer. The TRBC platform, from which HCW11-006 originates, is focused on multi-specific immunotherapeutic molecules, including second-generation T-cell engagers designed for solid tumors. Several companies are developing engineered cytokine therapies and immunocytokines targeting similar immune activation pathways. These include bifunctional cytokine constructs such as Sonnet BioTherapeutics’ IL-12/IL-15 fusion, IL-15–based agonists such as ImmunityBio’s approved Anktiva, and conditionally activated cytokine platforms from Werewolf Therapeutics. HCW11-006 differs in that it is designed as a multi-functional fusion protein incorporating cytokine signaling domains alongside checkpoint blockade within a single molecule. This “all-in-one” approach aims to replicate combination immunotherapy effects in a single construct. Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

临床1期引进/卖出免疫疗法基因疗法

2025-05-22

·抗体圈

免疫细胞因子：抗癌新武器如何实现 “精准爆破”？

摘要：免疫细胞因子通过靶向抗体将细胞因子集中于肿瘤部位，在癌症治疗中展现出延长细胞因子半衰期、减轻副作用等优势。本文深入剖析免疫细胞因子在临床前和临床应用的进展，探讨其分子结构、作用机制，分析新型细胞因子的潜力，同时针对安全性问题提出应对策略，旨在为下一代免疫细胞因子的设计和开发提供指导。一、引言：免疫细胞因子的崛起细胞因子在调节免疫反应和肿瘤微环境方面发挥着重要作用，具有强大的抗肿瘤潜力。然而，由于半衰期短和全身毒性等问题，许多细胞因子的临床应用受到限制。将抗体与细胞因子融合形成的免疫细胞因子，成为解决这些问题的有效策略。从图 1 中可以清晰看到细胞因子和免疫细胞因子用于癌症治疗的发展历程，近年来，免疫细胞因子的研究不断取得进展，越来越多的分子进入临床阶段，且研究趋势逐渐转向靶向免疫检查点如 PD-1/PD-L1。二、免疫细胞因子开发中常用的细胞因子2.1 IL-2IL-2 是用于开发免疫细胞因子的常用细胞因子之一。基于 IL-2 的免疫细胞因子在临床前和临床研究中都取得了不少成果。在临床前研究中，如 anti-CEA-IL-2、CBD-IL-2 等，展现出不同的抗肿瘤效果和特点；在临床研究中，罗氏开发的基于工程化 IL-2 变体的免疫细胞因子，以及 Innovent Biologics Inc. 开发的 anti-PD-1/IL-2 融合蛋白 IBI363 等，都显示出一定的潜力，具体信息可参考表 2。2.2 IL-15IL-15 对 NK 细胞和 CD8+ T 细胞的发育、存活和激活至关重要。众多基于 IL-15 的免疫细胞因子在临床前和临床研究中被开发，像 FIST15、N-809、LH01 等在临床前研究中表现出良好的抗肿瘤效果，HCW9218、KD033 等在临床研究中也展现出一定的安全性和有效性，详见表 3。2.3 IL-12IL-12 在免疫调节中具有重要作用，但临床应用受限于剂量限制性毒性。在临床前和临床研究中，多种基于 IL-12 的免疫细胞因子被探索，如 IL-12-F8-F8、NHS-IL12 等，它们在不同的肿瘤模型中表现出不同的效果，具体信息见表 4。2.4 IL-21IL-21 在增强 NK 细胞和 T 细胞的效应功能方面具有潜力，但也存在毒性和临床活性有限的问题。相关的免疫细胞因子如 αCD20-IL-21、PD1-Ab21 等在临床前研究中显示出一定的抗肿瘤效果，AMG256 等在临床研究中也在进一步探索其安全性和有效性，具体内容见表 5。2.5 IFNaIFNa 是首个获批用于肿瘤免疫治疗的细胞因子，但因副作用和半衰期短限制了应用。近年来，基于 IFNa 的免疫细胞因子在临床前和临床研究中逐渐受到关注，如 20-C2-2b、IGN002 等，具体信息见表 6。三、新兴的细胞因子和免疫细胞因子近年来，一些新的细胞因子如 IL-10、IL-18、IL-24 等在免疫细胞因子开发中展现出潜力。IL-10 以往被认为是免疫抑制性细胞因子，但现在发现其在肿瘤微环境中有促进免疫细胞增殖和浸润的作用；IL-18 具有抗肿瘤潜力，但受 IL-18 结合蛋白的限制，其突变体 DR-18 有望克服这一问题；IL-24 能抑制肿瘤侵袭和转移，在肿瘤治疗中具有很大潜力；TNF-α 在免疫细胞因子开发中应用存在争议，目前仅有 L19-TNF 进入临床阶段。四、应对免疫细胞因子安全性挑战的策略免疫细胞因子面临着 “细胞因子池” 效应和肿瘤靶向性差等问题，导致其在到达肿瘤部位前被循环中的受体捕获，积累到肿瘤部位的量少，且存在毒性。为解决这些问题，主要有以下策略：1.融合低活性细胞因子：降低细胞因子与受体的亲和力，可减少 “细胞因子池” 效应，延长半衰期，使免疫细胞因子更易在肿瘤部位积累，如基于 PD-1 的免疫细胞因子可选择性将 IL-2 或 IL-15 递送至 PD-1+CD8 + 肿瘤浸润淋巴细胞。2.条件激活的免疫细胞因子前药：利用肿瘤相关蛋白酶等特性，设计前药使细胞因子在肿瘤微环境中条件激活，减少在正常组织中的活性，降低毒性，目前已有多种相关研究和产品处于不同阶段。3.沉默抗体 Fc 功能：通过点突变沉默抗体的 Fc 功能，减少抗体相关的副作用，降低免疫细胞因子的整体毒性。4.优化抗体和细胞因子的选择与组合：不同的抗体和细胞因子组合对免疫细胞因子的安全性和抗肿瘤 efficacy 影响很大，需要根据其作用机制进行精细调整。五、总结与展望免疫细胞因子在癌症治疗中展现出巨大潜力，但目前仍处于研究早期。未来，需要进一步优化抗体和细胞因子的选择与组合，确保免疫细胞因子比联合治疗具有更高的安全性和有效性；继续利用细胞因子工程和前药策略提高安全性；探索与其他疗法的联合应用，增强抗肿瘤效果；开发携带不同有效载荷的免疫细胞因子，发挥多效抗肿瘤作用。随着研究的深入，免疫细胞因子有望在临床实践中得到广泛应用，为癌症患者带来新的希望。识别微信二维码，添加抗体圈小编，符合条件者即可加入抗体圈微信群！请注明：姓名+研究方向！本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场。

免疫疗法临床研究临床结果

2024-11-19

·GlobeNewswire-Health Care

HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules

MIRAMAR, Fla., Nov. 18, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 6,717,000 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced above market under Nasdaq rules. In a concurrent private placement, the Company also agreed to issue unregistered warrants to purchase up to an aggregate of 6,717,000 shares of common stock. The combined effective offering price for each share of common stock (or pre-funded warrant in lieu thereof) and accompanying warrants is $1.03. The warrants will have an exercise price of $1.03 per share, will be exercisable immediately, and expire on the five year anniversary from the date of issuance. The gross proceeds to the Company from the registered direct offering and concurrent private placement are estimated to be approximately $6.9 million before deducting the placement agent’s fees and other offering expenses payable by the Company. The offering is expected to close on or about November 20, 2024, subject to the satisfaction of customary closing conditions. Maxim Group LLC is acting as the sole placement agent in connection with the offering. The shares of common stock (or pre-funded warrants in lieu thereof) are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-266991), which was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on August 26, 2022. The offering of shares of common stock (or pre-funded warrants in lieu thereof) will be made only by means of a prospectus supplement that forms a part of such registration statement. The warrants to be issued in the concurrent private placement and the shares issuable upon exercise of such warrants were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”), and Regulation D promulgated thereunder and have not been registered under the Act or applicable state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. A prospectus supplement relating to the shares of common stock and pre-funded warrants will be filed by the Company with the SEC. When available, copies of the prospectus supplement relating to the registered direct offering, together with the accompanying prospectus, can be obtained at the SEC's website at www.sec.gov or from Maxim Group LLC, 300 Park Avenue, New York, NY 10022, Attention: Syndicate Department, or via email at syndicate@maximgrp.com or telephone at (212) 895-3500. About HCW Biologics: HCW Biologics is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular, diabetes, neurodegenerative, and autoimmune diseases, as well as other inflammatory conditions such as long-haul COVID-19. The Company has combined a deep understanding of disease-related immunology with its expertise in advanced protein engineering to develop two drug discovery platforms, each with a novel backbone which is used to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. The Company’s legacy drug discovery platform is its TOBI™ (Tissue factOr-Based fusIon) discovery platform, which has a Tissue-Factor based backbone. It was used to create HCW Biologics’ molecules: HCW9218, HCW9302, HCW9206 and HCW9201. The Company’s second drug discovery platform uses a unique protein-based backbone differentiated from Tissue Factor. Immunotherapeutics created with the Company’s two distinct drug discovery platforms have different characteristics and mechanisms of action, expanding the various pathways for treating senescence-associated disorders. The University of Pittsburgh Medical Center (UPMC) has agreed to include HCW9218 in an Investigator-sponsored Phase 2 clinical trial to evaluate patients with metastatic, advanced stage ovarian cancer in combination with neoadjuvant chemotherapy (NCT05145569). Forward-Looking Statements Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words and include, the statements on the closing of the offering and the satisfaction of closing conditions and use of proceeds in the offering, the Company’s ability to develop new immunotherapeutic treatments for non-oncology or oncology indications; the capabilities of the Company’s new platform and the effectiveness of new fusion proteins developed using the new platform. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties that are described in the section titled “Risk Factors” in the annual report on Form 10-K/A filed with the United States Securities and Exchange Commission (the “SEC”) on May 15, 2024, the latest Form 10-Q filed with the SEC on November 14, 2024, and in other filings filed from time to time with the SEC. Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law. Company Contact: Rebecca ByamChief Financial OfficerHCW Biologics Inc.RebeccaByam@hcwbiologics.com

免疫疗法临床2期

100 项与 HCW-9218 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
卵巢癌	临床2期	-	HCW Biologics Inc.	2024-05-10
胰腺癌	临床2期	美国	HCW Biologics Inc.	2022-10-17
不能切除性胰腺癌	临床2期	美国	ImmunityBio, Inc.	2022-10-17
衰老	临床前	美国	HCW Biologics Inc.	2025-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05322408 (HCW9218, CTgov)	临床1期	晚期恶性实体瘤	18	HCW9218	顧醖廠襯築簾齋範築餘 = 網製積築廠襯廠蓋夢顧窪構夢襯顧鏇願觸憲鑰 (鏇餘鹽襯衊壓鹹衊鹹淵, 襯齋網壓網襯鑰壓顧鏇 ~ 鹽壓願醖鑰鏇鏇鏇願艱)	-	2025-11-05
NCT05322408 (GlobeNewswire) 人工标引	临床1期	晚期恶性实体瘤	15	HCW9218	網艱糧鏇襯廠艱糧齋膚(獵鏇艱製鬱選網觸網憲) = without causing treatment-emergent skin lesions and bleeding events previously reported , without causing cytokine release syndrome. No liver enzyme elevation was observed. 築繭糧鬱憲築壓積網簾 (顧淵蓋夢獵壓繭築遞遞 )	积极	2023-11-08
NCT05322408 (GlobeNewswire) 人工标引	临床1期	晚期恶性实体瘤	15	HCW9218 (ovarian cancer)		积极	2023-11-08
NCT05322408 (HCW9218, SITC2023)	临床1期	晚期恶性实体瘤	12	HCW9218	鹽襯蓋繭衊網獵鏇鏇襯(窪襯艱襯簾夢範鬱醖鬱) = The most common adverse events are grade 1â2 injection site reactions and transient lymphopenia 顧夢遞構鬱膚鏇鬱餘廠 (遞製憲襯構糧製願觸壓 ) 更多	积极	2023-11-02
NCT05322408 (SITC 12022 \| SITC 22022) 人工标引	临床1期	HR阳性/HER2低表达实体瘤	3	HCW-9218	醖鬱選築襯繭範簾齋醖(築鬱築衊構鏇衊構網憲) = 蓋獵鑰糧醖鹹鹽鬱鹽鹹衊鹽願鑰廠餘壓衊繭壓 (獵鏇選醖糧夢構衊鏇鑰 ) 更多	积极	2022-11-01